Shares of Emergent Biosolutions, Inc. (NYSE:EBS) reached a new 52-week high during trading on Thursday . The company traded as high as $37.60 and last traded at $37.58, with a volume of 310,669 shares traded. The stock had previously closed at $36.47.

Several research analysts have recently weighed in on EBS shares. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Friday, August 25th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Emergent Biosolutions currently has a consensus rating of “Buy” and a consensus target price of $44.00.

The company’s 50-day moving average price is $35.77 and its 200 day moving average price is $32.23. The company has a market cap of $1.55 billion, a PE ratio of 23.94 and a beta of 1.23.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.26 by $0.13. The company had revenue of $100.77 million for the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.05) earnings per share. On average, analysts anticipate that Emergent Biosolutions, Inc. will post $1.54 EPS for the current fiscal year.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $35.50, for a total transaction of $887,500.00. Following the sale, the chairman now directly owns 1,655,216 shares in the company, valued at approximately $58,760,168. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jerome M. Hauer sold 10,776 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total transaction of $386,104.08. Following the sale, the director now owns 29,421 shares in the company, valued at $1,054,154.43. The disclosure for this sale can be found here. Insiders have sold a total of 84,337 shares of company stock worth $3,065,292 over the last 90 days. Corporate insiders own 16.50% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Sei Investments Co. grew its stake in shares of Emergent Biosolutions by 97,546.2% during the 2nd quarter. Sei Investments Co. now owns 38,082 shares of the biopharmaceutical company’s stock worth $1,291,000 after acquiring an additional 38,043 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Emergent Biosolutions by 31.0% during the 1st quarter. Bank of America Corp DE now owns 234,902 shares of the biopharmaceutical company’s stock worth $6,821,000 after acquiring an additional 55,626 shares in the last quarter. Airain ltd bought a new position in shares of Emergent Biosolutions during the 1st quarter worth approximately $461,000. Congress Asset Management Co. MA grew its stake in shares of Emergent Biosolutions by 9.8% during the 2nd quarter. Congress Asset Management Co. MA now owns 52,080 shares of the biopharmaceutical company’s stock worth $1,766,000 after acquiring an additional 4,632 shares in the last quarter. Finally, Federated Investors Inc. PA grew its stake in shares of Emergent Biosolutions by 3.4% during the 2nd quarter. Federated Investors Inc. PA now owns 245,002 shares of the biopharmaceutical company’s stock worth $8,308,000 after acquiring an additional 8,098 shares in the last quarter. 85.44% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Emergent Biosolutions, Inc. (EBS) Hits New 1-Year High at $37.60” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/07/emergent-biosolutions-inc-ebs-hits-new-1-year-high-at-37-60.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.